174 related articles for article (PubMed ID: 37272673)
1. Autoimmune nodo-paranodopathies 10 years later: Clinical features, pathophysiology and treatment.
Uncini A
J Peripher Nerv Syst; 2023 Jul; 28 Suppl 3():S23-S35. PubMed ID: 37272673
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground.
Uncini A; Vallat JM
J Neurol Neurosurg Psychiatry; 2018 Jun; 89(6):627-635. PubMed ID: 29248893
[TBL] [Abstract][Full Text] [Related]
3. New classification of autoimmune neuropathies based on target antigens and involved domains of myelinated fibres.
Uncini A; Mathis S; Vallat JM
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):57-67. PubMed ID: 34373238
[TBL] [Abstract][Full Text] [Related]
4. Ultrastructural Lesions of Nodo-Paranodopathies in Peripheral Neuropathies.
Vallat JM; Magy L; Corcia P; Boulesteix JM; Uncini A; Mathis S
J Neuropathol Exp Neurol; 2020 Mar; 79(3):247-255. PubMed ID: 31923310
[TBL] [Abstract][Full Text] [Related]
5. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies.
Uncini A; Susuki K; Yuki N
Clin Neurophysiol; 2013 Oct; 124(10):1928-34. PubMed ID: 23639374
[TBL] [Abstract][Full Text] [Related]
6. Nodopathies of the peripheral nerve: an emerging concept.
Uncini A; Kuwabara S
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1186-95. PubMed ID: 25699569
[TBL] [Abstract][Full Text] [Related]
7. Nodo-paranodopathies: Concepts, Clinical Implications, and Management.
Khadilkar SV; Kamat S; Patel R
Ann Indian Acad Neurol; 2022; 25(6):1001-1008. PubMed ID: 36911467
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic mechanisms in inflammatory and paraproteinaemic peripheral neuropathies.
Rinaldi S; Bennett DL
Curr Opin Neurol; 2014 Oct; 27(5):541-51. PubMed ID: 25159930
[TBL] [Abstract][Full Text] [Related]
9. The electrophysiology of axonal neuropathies: More than just evidence of axonal loss.
Uncini A; Santoro L
Clin Neurophysiol; 2020 Oct; 131(10):2367-2374. PubMed ID: 32828039
[TBL] [Abstract][Full Text] [Related]
10. Diabetes Mellitus Is a Possible Risk Factor for Nodo-paranodopathy With Antiparanodal Autoantibodies.
Appeltshauser L; Messinger J; Starz K; Heinrich D; Brunder AM; Stengel H; Fiebig B; Ayzenberg I; Birklein F; Dresel C; Dorst J; Dvorak F; Grimm A; Joerk A; Leypoldt F; Mäurer M; Merl P; Michels S; Pitarokoili K; Rosenfeldt M; Sperfeld AD; Weihrauch M; Welte GS; Sommer C; Doppler K
Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35314491
[TBL] [Abstract][Full Text] [Related]
11. Another brick in the wall: is hexane neuropathy a 'nodo-paranodopathy'?
Alpaydin Baslo S; Ozturk O; Dayan C; Atakli D; Baslo MB
Acta Neurol Belg; 2021 Apr; 121(2):373-378. PubMed ID: 30982200
[TBL] [Abstract][Full Text] [Related]
12. Electrodiagnostic Assessment of Polyneuropathy.
Vazquez Do Campo R
Neurol Clin; 2021 Nov; 39(4):1015-1034. PubMed ID: 34602212
[TBL] [Abstract][Full Text] [Related]
13. Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment response.
Bresciani L; Salvalaggio A; Vegezzi E; Visentin A; Fortuna A; Anglani M; Cacciavillani M; Masciocchi S; Scaranzin S; Carecchio M; Martinuzzi A; Gastaldi M; Briani C
J Peripher Nerv Syst; 2023 Sep; 28(3):522-527. PubMed ID: 37246762
[TBL] [Abstract][Full Text] [Related]
14. Reversible conduction failure in overlap of Miller Fisher syndrome and pharyngeal-cervical-brachial variant of Guillain-Barré syndrome in the spectrum of nodo-paranodopathies.
Gürsoy AE; Kolukısa M; Babacan-Yıldız G; Altıntaş Ö; Yaman A; Asil T
J Clin Neurosci; 2014 Jul; 21(7):1269-71. PubMed ID: 24534627
[TBL] [Abstract][Full Text] [Related]
15. Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage.
Appeltshauser L; Junghof H; Messinger J; Linke J; Haarmann A; Ayzenberg I; Baka P; Dorst J; Fisse AL; Grüter T; Hauschildt V; Jörk A; Leypoldt F; Mäurer M; Meinl E; Michels S; Motte J; Pitarokoili K; Stettner M; Villmann C; Weihrauch M; Welte GS; Zerr I; Heinze KG; Sommer C; Doppler K
Brain; 2023 May; 146(5):1932-1949. PubMed ID: 36346134
[TBL] [Abstract][Full Text] [Related]
16. Antisulfatide antibodies in neuropathy: clinical and electrophysiologic correlates.
Dabby R; Weimer LH; Hays AP; Olarte M; Latov N
Neurology; 2000 Apr; 54(7):1448-52. PubMed ID: 10751255
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathies.
Svahn J; Antoine JC; Camdessanché JP
Rev Neurol (Paris); 2014 Dec; 170(12):808-17. PubMed ID: 25459126
[TBL] [Abstract][Full Text] [Related]
18. Nodal and paranodal antibody-associated neuropathies.
Fehmi J; Vale T; Keddie S; Rinaldi S
Pract Neurol; 2021 May; ():. PubMed ID: 34039750
[TBL] [Abstract][Full Text] [Related]
19. A common mechanism and a new categorization for anti-ganglioside antibody-mediated neuropathies.
Uncini A
Exp Neurol; 2012 Jun; 235(2):513-6. PubMed ID: 22507308
[TBL] [Abstract][Full Text] [Related]
20. Antibody- and macrophage-mediated segmental demyelination in chronic inflammatory demyelinating polyneuropathy: clinical, electrophysiological, immunological and pathological correlates.
Vallat JM; Mathis S; Vegezzi E; Richard L; Duchesne M; Gallouedec G; Corcia P; Magy L; Uncini A; Devaux J
Eur J Neurol; 2020 Apr; 27(4):692-701. PubMed ID: 31769579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
